As much as SARS-CoV-2 has altered the way humans live since the beginning of 2020, this virus's deadly nature has required clinical testing to meet 2020's demands of higher throughput, higher accuracy and higher efficiency. Information technology has allowed institutions, like Arizona State University (ASU), to make strategic and operational changes to combat the SARS-CoV-2 pandemic. At ASU, information technology was one of the six facets identified in the ongoing review of the ASU Biodesign Clinical Testing Laboratory (ABCTL) among business, communications, management/training, law, and clinical analysis. The first chapter of this manuscript covers the background of clinical laboratory automation and details the automated laboratory workflow to perform ABCTL’s COVID-19 diagnostic testing. The second chapter discusses the usability and efficiency of key information technology systems of the ABCTL. The third chapter explains the role of quality control and data management within ABCTL’s use of information technology. The fourth chapter highlights the importance of data modeling and 10 best practices when responding to future public health emergencies.

Developing a vaccine during the midst of a pandemic requires a careful balance between <br/>speed, safety, and efficacy. For the COVID-19 pandemic, the U.S. implemented Operation Warp Speed to accelerate the timeline for vaccine development. The FDA also imposed specific guidelines for granting Emergency Use Authorization (EUA). As of April 1st, 2021, Operation Warp Speed resulted in three different vaccines receiving EUA, all of which are currently being administered to the public. However, the rapid production and changes in the approval process intensified public scrutiny on the safety and efficacy of the vaccine. This thesis analyzes the differences in fast-tracking a vaccine, which consolidated the authorization process into months rather than years, and delineates the main concerns of the public regarding the COVID-19 vaccine through a media analysis. Although the EUA raised questions about the safety of the vaccine, polls indicate that most Americans would still be willing to receive the vaccine.